Composition containing β-nicotinamide mononucleotide and chlorogenic acid and application thereof

Through the combination of β-nicotinamide single nucleotide and chlorogenic acid, the three factors of high levels are reduced in synergistically, and the treatment problems of non-toxic and side effects in the prior art are solved, and significant weight loss and blood sugar reduction are achieved. , lowering blood pressure and lowering blood lipid effects.

CN115702904BActive Publication Date: 2024-11-01CHENGDU CHUANYU JIANWEI BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110914287.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-08-10
Publication Date
2024-11-01
Estimated Expiration
2041-08-10

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce the three highs (diabetes, hypertension, hyperlipidemia) factors without toxicity and side effects, especially the treatment effect of patients with cardiovascular disease is not significant enough.

Method used

Provided is a composition comprising β-nicotinamide single nucleotide and chlorogenic acid, whose active ingredient consists of 30-70% of β-nicotinamide single nucleotide and chlorogenic acid, and is used to prepare the Medicines for weight loss, lowering blood sugar, lowering blood pressure and lowering blood lipids.

Benefits of technology

The composition significantly reduces weight, reduces blood sugar and blood pressure, reduces blood lipids, is low in cost, has no toxic side effects, and is suitable for long-term use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115702904B_ABST
    Figure CN115702904B_ABST
Patent Text Reader

Abstract

The present invention relates to a composition comprising β-nicotinamide mononucleotide and chlorogenic acid and its application, and belongs to the field of biomedicine technology. The technical problem solved by the present invention is to provide a composition comprising β-nicotinamide mononucleotide and chlorogenic acid. The active ingredients of the composition are composed of the following components in weight percentage: 30-70% of β-nicotinamide mononucleotide, and the rest is chlorogenic acid. The present invention compounded NMN with chlorogenic acid, and the two synergized to have significant weight loss, blood sugar lowering, blood pressure lowering and blood lipid lowering effects. In addition, the composition of the present invention has low cost and is easy to promote.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition comprising beta-nicotinamide mononucleotide and chlorogenic acid and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Cardiovascular diseases (CVD) are one of the non-communicable diseases with the highest morbidity and mortality rates in the world. It is estimated that there are about 290 million CVD patients in my country. CVD includes various diseases, such as vascular disease, heart failure, coronary artery disease, myocardial ischemia and hypertension. There are many factors that cause CVD, among which diabetes, hypertension, hyperlipidemia, obesity and other factors are the main causes of cardiovascular disease. At present, people with three highs in the market mainly use drugs to regulate and control the three highs. Long-term use of drugs is prone to certain side effects. Therefore, how to develop a composition that is non-toxic, has no side effects and has significant effects while reducing the three highs has become a problem that needs to be solved urgently in the existing technology. Studies have shown that natural products have good efficacy and application prospects in the protection of the cardiovascular system and the prevention and treatment of CVD.

[0003] β-Nicotinamide mononucleotide (abbreviated as NMN) is a naturally occurring bioactive nucleotide that has important physiological functions for human cells. It can be naturally synthesized in cells and can also be derived from a variety of foods such as broccoli, cabbage, cucumber, edamame, etc. Studies have shown that NMN has a certain effect in reducing the weight of mice and improving blood sugar and blood lipids. However, the effect of NMN alone needs to be further improved. Summary of the invention

[0004] In view of the above defects, the technical problem solved by the present invention is to provide a composition comprising β-nicotinamide mononucleotide and chlorogenic acid, which has good weight loss, blood sugar lowering, blood pressure lowering and blood lipid lowering effects.

[0005] The present invention comprises a composition of β-nicotinamide mononucleotide and chlorogenic acid, wherein the active ingredients are composed of the following components in percentage by weight: 30-70% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

[0006] In a specific embodiment of the present invention, the active ingredient of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid consists of the following components in weight percentage: 40-60% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

[0007] In one embodiment of the present invention, the active ingredient of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid is composed of the following components in weight percentage: 60% of β-nicotinamide mononucleotide and the rest of chlorogenic acid. In another embodiment of the present invention, the active ingredient of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid is composed of the following components in weight percentage: 50% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

[0008] The present invention comprises a composition of β-nicotinamide mononucleotide and chlorogenic acid, and also comprises pharmaceutically acceptable auxiliary materials.

[0009] In one embodiment of the present invention, the composition comprising β-nicotinamide mononucleotide and chlorogenic acid is in the form of granules, tablets, capsules, pills or pastes.

[0010] The present invention also provides use of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid of the present invention in the preparation of medicines for reducing weight, lowering blood sugar, lowering blood pressure or lowering blood lipids.

[0011] The present invention comprises a composition of β-nicotinamide mononucleotide and chlorogenic acid. The β-nicotinamide mononucleotide and chlorogenic acid are compounded, and the two have synergistic effects, and can be used in the preparation of medicines with weight loss, blood sugar lowering, blood pressure lowering or blood lipid lowering effects.

[0012] Compared with the prior art, the present invention has the following beneficial effects:

[0013] The present invention combines NMN with chlorogenic acid, and the two synergize to enhance the effect, and have significant weight loss, blood sugar, blood pressure and blood lipid lowering effects. In addition, the composition of the present invention has low cost and is easy to promote. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 The figure shows the effects of each group of drugs on fasting blood glucose in Test Example 1 of the present invention.

[0015] Figure 2 This is the effect of each group of drugs on triglycerides in Test Example 1 of the present invention.

[0016] Figure 3 This is the effect of each group of drugs on the amount of alanine aminotransferase in Test Example 1 of the present invention.

[0017] Figure 4 This is the effect of each group of drugs in Test Example 1 of the present invention on the amount of aspartate aminotransferase.

[0018] Figure 5 This is the therapeutic effect of the composition of Example 4 in Test Example 1 of the present invention on fatty liver.

[0019] Figure 6This is the effect of the composition of Example 4 in Test Example 2 of the present invention on the systolic and diastolic blood pressure of rats (n=10). DETAILED DESCRIPTION

[0020] The present invention comprises a composition of β-nicotinamide mononucleotide and chlorogenic acid, wherein the active ingredients are composed of the following components in percentage by weight: 30-70% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

[0021] Chlorogenic acid is one of the main active ingredients of many Chinese herbal medicines such as honeysuckle, eucommia bark, and capillaris, and is also an important active ingredient in many fruits and vegetables. Studies have shown that chlorogenic acid has a wide range of biological activities, including lowering blood pressure, lowering blood lipids, antibacterial, antiviral, anti-tumor, scavenging free radicals and stimulating the central nervous system.

[0022] The composition of the present invention is composed of raw materials β-nicotinamide mononucleotide and chlorogenic acid, which are both medicinal and edible. Through the mutual coordination and synergistic effect of each component, the purpose of synergistic enhancement is achieved, so that it has significant weight loss, blood sugar, blood pressure and blood lipid lowering effects. In addition, the raw materials of the present invention are easy to obtain, inexpensive, effective, non-toxic, and have no side effects, and are suitable for long-term use.

[0023] In a specific embodiment of the present invention, the active ingredient of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid consists of the following components in weight percentage: 40-60% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

[0024] In one embodiment of the present invention, the active ingredient of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid is composed of the following components in weight percentage: 60% of β-nicotinamide mononucleotide and the rest of chlorogenic acid. In another embodiment of the present invention, the active ingredient of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid is composed of the following components in weight percentage: 50% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

[0025] The present invention comprises a composition of β-nicotinamide mononucleotide and chlorogenic acid, and also comprises pharmaceutically acceptable auxiliary materials.

[0026] The dosage form commonly used in the art can be prepared by adding auxiliary materials. In one embodiment of the present invention, the composition comprising β-nicotinamide mononucleotide and chlorogenic acid is a granule, tablet, capsule, pill or paste.

[0027] The composition of the present invention comprising β-nicotinamide mononucleotide and chlorogenic acid can be prepared by conventional methods. In one embodiment of the present invention, it can be prepared by the following method:

[0028] The β-nicotinamide mononucleotide, chlorogenic acid and auxiliary materials are uniformly mixed to obtain the composition containing β-nicotinamide mononucleotide and chlorogenic acid.

[0029] The present invention also provides use of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid of the present invention in the preparation of medicines for reducing weight, lowering blood sugar, lowering blood pressure or lowering blood lipids.

[0030] The present invention comprises a composition of β-nicotinamide mononucleotide and chlorogenic acid. The β-nicotinamide mononucleotide and chlorogenic acid are compounded, and the two have synergistic effects, and can be used in the preparation of medicines with weight loss, blood sugar lowering, blood pressure lowering or blood lipid lowering effects.

[0031] The specific implementation modes of the present invention are further described below in conjunction with embodiments, but the present invention is not limited to the scope of the embodiments.

[0032] Example 1

[0033] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 30% β-nicotinamide mononucleotide and 70% chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0034] Example 2

[0035] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 40% β-nicotinamide mononucleotide and 60% chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0036] Example 3

[0037] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 50% β-nicotinamide mononucleotide and 50% chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0038] Example 4

[0039] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 60% of β-nicotinamide mononucleotide and 40% of chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0040] Example 5

[0041] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 70% β-nicotinamide mononucleotide and 30% chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0042] Comparative Example 1

[0043] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 10% of β-nicotinamide mononucleotide and 90% of chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0044] Comparative Example 2

[0045] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 20% β-nicotinamide mononucleotide and 80% chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0046] Comparative Example 3

[0047] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 80% of β-nicotinamide mononucleotide and 20% of chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0048] Comparative Example 4

[0049] This embodiment provides a composition, the total mass of the composition is 25 g, wherein the mass fractions of the main components of the composition are: 90% of β-nicotinamide mononucleotide and 10% of chlorogenic acid. The two raw materials are weighed in proportion and mixed evenly.

[0050] Experimental Example 1 Effect of the composition on body weight, blood sugar and blood lipids in a high-fat diet-induced obese mouse model

[0051] Establishment of high-fat diet-induced obesity mouse model:

[0052] Five-week-old C57BL / 6J mice were used, half male and half female. Ten mice were randomly selected as the normal control group and fed with ordinary feed, and the remaining mice were fed with high-fat feed for 10 weeks. When fasting blood glucose was ≥6.8 mmol / L and the body weight was greater than 35 g, the mouse model was considered to be successfully established. The mice with successful modeling were randomly divided into groups, with 10 mice in each group, and NMN, chlorogenic acid, and the composition of Examples 1 to 5 and Comparative Examples 1 to 4 were given 100 mg / kg, respectively. The composition was dissolved in 0.3 mL of normal saline, and the blank control group and the normal control group were given the same volume of normal saline. At the same time, a positive drug rosiglitazone group (15 mg / kg) was set up. The drug was administered once a day for 8 consecutive weeks. Changes in weight, food intake and body temperature of mice in different groups were recorded. After 8 weeks of treatment, the mice were killed, and blood biochemical indicators such as blood sugar, serum triglycerides, alanine aminotransferase, and aspartate aminotransferase were tested, and HE staining was performed on important organs such as heart, liver, spleen, lung, and kidney. The effects of the composition on the body weight of mice are shown in Table 1, and the effects on fasting blood glucose are shown in Table Figure 1 , the effect on triglycerides Figure 2 , the effect on the amount of alanine aminotransferase is shown in Figure 3 , the effect on the amount of aspartate aminotransferase is shown in Figure 4 The therapeutic effect of the composition of Example 4 on fatty liver is shown in Figure 5 . Wherein, Normal represents the normal group, NS represents the blank control group, Rosi represents the rosiglitazone group, CA represents the chlorogenic acid group, E1 to E5 represent the Example 1 to Example 5 groups respectively (i.e., E1 is the Example 1 composition group, E2 is the Example 2 composition group, E3 is the Example 3 composition group, E4 is the Example 4 composition group, and E5 is the Example 5 composition group), and C1 to C4 represent the Comparative Examples 1 to 4 groups respectively (i.e., C1 is the Comparative Example 1 composition group, C2 is the Comparative Example 2 composition group, C3 is the Comparative Example 3 composition group, and C4 is the Comparative Example 4 composition group).

[0053] Table 1 Effect of the composition on the body weight of mice

[0054]

[0055] From Table 1, Figure 1 to Figure 4 It can be seen that NMN and chlorogenic acid (CA) have a certain effect on the weight, blood sugar, triglycerides, alanine aminotransferase, and aspartate aminotransferase of mice. With the change of the ratio of NMN and chlorogenic acid, the composition has a significant effect on reducing the above indicators. In particular, the composition of Example 4 has a very significant effect on weight loss, lowering blood sugar, lowering blood lipids, and reducing the amount of alanine aminotransferase and aspartate aminotransferase. Figure 5 It can be seen that the composition of Example 4 also has a significant therapeutic effect on fatty liver induced by a high-fat diet.

[0056] Test Example 2 Effect of the composition on blood pressure in rats

[0057] According to the results of Test Example 1, the composition of Example 4 has significant weight loss, blood sugar lowering and blood lipid lowering effects compared with NMN and chlorogenic acid. This test example studies the blood pressure lowering effect of the composition of Example 4.

[0058] (1) Experimental animals:

[0059] 80 rats with essential hypertension (SHR) and 10 healthy normotensive (WKY) rats were selected, half male and half female, with a body weight of (250±10) g. The rats were housed in cages, 5 in each cage, at room temperature (22±2)℃, natural light, relative humidity 60%-65%, and free access to drinking water and food. After 2 weeks of adaptive feeding, the blood pressure of the rats was measured once a week. SHR rats (60) with systolic blood pressure greater than 180 mmHg (1 mmHg=0.133 kPa) were selected for the experiment, and 10 WKY rats were selected as blank controls.

[0060] (2) Grouping, dosing and measurement:

[0061] 60 SHR rats were randomly divided into normal saline group, captopril group, NMN group, chlorogenic acid group, low-dose group of Example 4, high-dose group of Example 4, with 10 rats in each group, and 10 WKY rats were selected as the control group, for a total of seven groups. The NMN group was given 100 mg / kg of NMN, the chlorogenic acid group was given 100 mg / kg of chlorogenic acid, the high-dose group of Example 4 was given 100 mg / kg of the composition, the low-dose group of Example 4 was given 50 mg / kg of the composition, the captopril group was given 20 mg / kg of captopril suspension, and the control group and normal saline group were given the same amount of normal saline. The body weight of each group was measured once a week, and the dosage for the next week was adjusted according to the body weight, and the medication was continued for 8 weeks. The tail artery blood pressure of rats in the awake resting state was measured using the BP-100A fully automatic non-invasive blood pressure measurement system, and the average value was taken once a week. The results are shown in Table 1. Figure 6 .

[0062] Depend on Figure 6 It can be seen that compared with the model group, the systolic and diastolic blood pressures of each drug administration group decreased from the second week of administration, and the downward trend became more obvious as the administration time prolonged. The blood pressure lowering effect of chlorogenic acid was better than that of NMN. The composition of Example 4 of the present invention, at a low dose, was slightly inferior to the captopril group in reducing the systolic and diastolic blood pressure of rats, but at a high dose, it was better than the captopril group in reducing the systolic and diastolic blood pressure of rats, indicating that the composition of the present invention has a very good blood pressure lowering effect.

[0063] In summary, after combining NMN with chlorogenic acid, the resulting composition achieves an unexpected synergistic effect in weight loss, lowering blood sugar, lowering blood lipids and lowering blood pressure.

Claims

1. A composition comprising β-nicotinamide mononucleotide and chlorogenic acid, characterized in that: The active ingredients are composed of the following components in percentage by weight: 60% of β-nicotinamide mononucleotide and the rest of chlorogenic acid.

2. The composition comprising β-nicotinamide mononucleotide and chlorogenic acid according to claim 1, characterized in that: Also included are pharmaceutically acceptable excipients.

3. The composition comprising β-nicotinamide mononucleotide and chlorogenic acid according to claim 1, characterized in that: The composition of β-nicotinamide mononucleotide and chlorogenic acid is in the form of granules, tablets, capsules, pills or pastes.

4. Use of the composition comprising β-nicotinamide mononucleotide and chlorogenic acid according to any one of claims 1 to 3 in the preparation of a drug for reducing weight, lowering blood sugar, lowering blood pressure or lowering blood lipids.